Pfizer tests new paxlovid pill formulation
NCT ID NCT06397144
Summary
This study aimed to see if a new, combined tablet form of the COVID-19 antiviral drug nirmatrelvir/ritonavir (Paxlovid) works the same way in the body as the currently available separate tablets. It involved healthy adult volunteers who took single doses of the different tablet forms while fasting. The main goal was to compare how the body absorbs the drugs from each formulation and to check for safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.